Renaissance Technologies LLC boosted its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 5.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 606,538 shares of the company’s stock after acquiring an additional 28,990 shares during the period. Renaissance Technologies LLC owned about 4.25% of Surmodics worth $25,499,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. US Bancorp DE raised its position in shares of Surmodics by 61.9% in the fourth quarter. US Bancorp DE now owns 16,190 shares of the company’s stock valued at $589,000 after buying an additional 6,193 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Surmodics in the fourth quarter valued at approximately $504,000. Mesirow Financial Investment Management Inc. acquired a new position in shares of Surmodics in the first quarter valued at approximately $223,000. BNP Paribas Financial Markets raised its position in shares of Surmodics by 7.5% in the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after buying an additional 481 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares during the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.
Surmodics Price Performance
Surmodics stock opened at $39.40 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.44. The firm has a 50 day moving average price of $40.45 and a 200 day moving average price of $36.11. The company has a market cap of $562.24 million, a price-to-earnings ratio of 41.47 and a beta of 1.20.
Wall Street Analysts Forecast Growth
SRDX has been the subject of a number of analyst reports. Lake Street Capital reissued a “hold” rating and issued a $43.00 price objective on shares of Surmodics in a research report on Wednesday, May 29th. StockNews.com began coverage on shares of Surmodics in a research report on Friday. They issued a “hold” rating for the company. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Monday, August 5th. Barrington Research restated a “market perform” rating on shares of Surmodics in a report on Thursday, May 30th. Finally, Sidoti restated a “neutral” rating and issued a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $50.00.
View Our Latest Stock Report on Surmodics
Surmodics Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Featured Stories
- Five stocks we like better than Surmodics
- Manufacturing Stocks Investing
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.